New Drug Application Filing for Ibrutinib Accepted in Two B-cell Malignancies by the U.S. FDA

Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing its New Drug Application for the investigational oral Bruton's tyrosine kinase inhibitor ibrutinib, for two B-cell malignancy indications: previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia /small ... (more)

http://www.drugs.com/nda/ibrutinib_130829.html?